- Poster presentation
- Open Access
BNZ-gamma peptide, a potential therapeutic agent in HTLV-1 associated myelopathy
© Massoud et al; licensee BioMed Central Ltd. 2014
- Published: 7 January 2014
- Potential Therapeutic Agent
- Gamma Chain
- Chain Receptor
- Pathogenic Effector
- Pegylated Form
The precise mechanism of HAM/TSP pathogenesis remains unclear however many findings suggest that HTLV-1 can activate the infected lymphocytes in the peripheral circulation leading to enhanced migration into the CNS. Once in this compartment, there is preferential expansion of the infected cells and a compartmentalized interaction between virus-specific CD8+ T-cells and virus- infected CD4+ lymphocytes leading to bystander damage of neural tissues. Dysregulation of T cells activation has been reported in HAM/TSP, particularly dependent on the induction of the stimulatory cytokine loops IL-2/IL-2Rα, IL-15/IL-15Rα and IL-9/IL-9Rγ by the virus. All these cytokines share a common chain receptor, the gamma chain (γC), offering a potential therapeutic target. BNZ- γ is a 19-mer peptide, that was designed based on the presence of a moderately conserved region shared by all six members of the Gamma cytokine family (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) in their D-helix structure. In vitro, we showed that BNZ- γ selectively blocks binding and downstream signaling of Il-2, IL-9 and IL-15. In PBMC of HAM/TSP patients, BNZ-γ suppressed ex–vivo spontaneous proliferation (SP) in the majority of the tested samples. Additionally a pegylated form of the peptide (N-PEG40) could suppress SP, CD25 expression and STAT5 phosphorylation in the CD8+ T-cells. More importantly, N-PEG40 decreased proliferation of Tax-specific CD8+ cells, a known pathogenic effector cell in HAM/TSP. We are currently studying its effects on functional markers of effector /memory T-cells. These results suggest that manipulation of the inflammatory cytokine loops may be of therapeutic value in the treatment of HAM/TSP.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.